We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Giemsa Stain Outperforms Urease Test for Helicobacter Pylori Diagnosis

By LabMedica International staff writers
Posted on 05 May 2020
More than 50% of the worldwide population is infected by Helicobacter pylori which is harbored in their upper gastrointestinal tract. More...
Despite having chronic gastritis, most people infected by H. pylori are asymptomatic and have no specific clinical signs and symptoms.

Giemsa stain and rapid urease test (CLO test) are the most performed tests of H. pylori infection at first‐line clinical examination because of their simplicity and reliability. However, the sensitivity of CLO test is significantly reduced in patients with atrophic gastritis and intestinal metaplasia, and the disadvantages of Giemsa stain are higher cost and time‐consuming.

Medical scientists at the Taiwanese National Health Research Institutes (Zhunan, Taiwan) collected and retrieved tissue specimens of 233 patients with gastritis or/and gastric ulcer from diagnostic resection specimens. Tissue specimens of gastric mucosa were separated into three parts for the traditional Giemsa stain, modified Giemsa stain, and CLO test. For the CLO test (Kimberly‐Clark, Irving TX, USA), 2‐3 mm specimen was placed into medium containing urea and examined.

The scientists reported that the modified Giemsa stain was comparable to the traditional one. Statistical analysis indicated that the modified Giemsa stain obtains greater accuracy in H. pylori‐infected patients with gastritis and ulcer than the CLO test (48.1% versus 43.7%). Moreover, considering the prognosis of different symptoms of gastric diseases, the modified Giemsa stain has a more accurate prognosis than combination symptoms. Seventy‐seven of the 173 gastritis patients (44.5%) were diagnosed as positive for H. pylori infection and 96 (55.5%) as negative by the modified Giemsa stain.

The authors concluded that the modified Giemsa stain was more simplified and time‐saving than traditional Giemsa stain, which is comparable to the traditional one and was confirmed to be better than CLO test using 233 H. pylori‐infected patients with gastric disease. In clinical examination, this modified Giemsa stain can be applied to routine examination and provides quick and accurate diagnosis and prognosis to H. pylori‐infected patients with gastric diseases. The study was published in the April, 2020 issue of the Journal of Clinical Laboratory Analysis.

Related Links:
Taiwanese National Health Research Institutes
Kimberly‐Clark



New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Left is the original cell image and right is same cell image zoomed in and rendered in the special imaging software (Photo courtesy of FIU)

Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear

Alzheimer’s disease affects millions globally, but patients are often diagnosed only after memory loss and other symptoms appear, when brain damage is already extensive. Detecting the disease much earlier... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.